Drug Guidance
View all drug guidances and details here.
226 items
6 October 2026
Capivasertib in combination with fulvestrant for HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration
Condition
Breast
Cancer
-
Drug guidance
5 October 2026
Biologics for treating atopic dermatitis
Condition
Skin
-
Drug guidance
5 October 2026
Icatibant and sebetralstat for treating hereditary angioedema attacks
Condition
Blood and Immune System
-
Drug guidance
5 October 2026
Equecabtagene autoleucel for relapsed or refractory multiple myeloma
Condition
Cancer
-
Drug guidance
5 October 2026
Selexipag for treating pulmonary arterial hypertension
Condition
Cardiovascular
Drug guidance
5 October 2026
Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
Condition
Cancer
Respiratory
Drug guidance
5 October 2026
Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
Condition
Cancer
Gastrointestinal tract
Drug guidance
5 October 2026
Pembrolizumab for the adjuvant treatment of renal cell carcinoma
Condition
Cancer
Kidney
Drug guidance
5 October 2026
Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
Condition
Cancer
Gynaecological
Drug guidance
5 October 2026
Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
Condition
Breast
Cancer
Drug guidance